The challenge for CHM is getting up enough speed to exit the death spiral.
I think our MC has become so ridiculously low simply due to funding concerns.
You'd hope that this hugely dilutive raise will give us the runway and momentum required to get significant results and rerate in before the next raise. Tough ask.
Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-40
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
